Express Pharma

AstraZeneca and Neurimmune ink $760 million deal for antibody drug

Under the agreement, Alexion would pay Neurimmune an upfront payment of $30 million and it would be eligible for payments of up to $730 million upon completion of some targets, plus royalties on sales

0 245